ArticleNeural plasticity2026
Targeting Nurr1 With Amodiaquine Preserves Dendritic Spines and Cognitive Function After Chronic Cerebral Hypoperfusion.
Article in Neural plasticity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Nurr1 With Amodiaquine Preserves Dendritic Spines and Cognitive Function After Chronic Cerebral Hypoperfusion.Neural plasticity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNurr1, an orphan nuclear receptor that lacks an endogenous ligand, plays a key role in hippocampal function, synaptic plasticity, and cognitive processes. It is linked to various central nervous system diseases; however, its association with chronic cerebral hypoperfusion (CCH)-induced cognitive impairment remains unclear. This study investigated whether the Nurr1 agonist, amodiaquine (AQ), can enhance synaptic plasticity and alleviate cognitive deficits caused by CCH.
methodsA CCH rat model was created using the bilateral common carotid arterial occlusion method, followed by a 2-week AQ treatment (20 mg/kg, every 12 h, through intraperitoneal injection). Learning and spatial memory were assessed using the Morris water maze (MWM), Y-maze, and object recognition tests. Cerebral blood flow (CBF) in the cortex and hippocampus was measured using arterial spin labeling (ASL) with 3.0T magnetic resonance imaging (MRI), and white matter fiber density was assessed using diffusion tensor imaging (DTI). Hippocampal neuron morphology and count were examined using Nissl and NeuN staining, while dendritic spine morphology and density in CA1 and CA3 hippocampal regions were analyzed using Golgi staining.
resultsExperiments with the water maze, Y-maze, and object recognition tests demonstrated that CCH rats treated with AQ exhibited improved long-term and short-term memory and spatial recognition compared to the control group, with benefits persisting after two and 6 weeks. MRI DTI sequences revealed that AQ reversed the decline in white matter fiber density observed in CCH model rats compared to the sham group. Golgi staining confirmed that AQ protected the dendritic spines of the neurons damaged in the CCH model.
conclusionAdministrating Nurr1 agonist AQ demonstrated a sustained ameliorative effect on cognitive deficits in CCH rats. This effect is potentially mediated through the mitigation of hippocampal neuronal loss and improvement of dendritic spine integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.